#55 Mapping The Human Immune System: Using AI To Change Drug Development With Noam Solomon

AI has gone so far as to potentially change drug development, and these developments have the potential to make a difference in people’s lives. On this episode of BioTech IQ, Ammon interviews Noam Solomon, the CEO of Immunai. Immunai is developing an AI platform that leverages big data, single cell multiomics, and machine learning to bridge the gap between casual immunology and translational disease biology. Their platform is mapping the human immune system at an unprecedented level of granularity, allowing them to identify the right targets to go after. In this interview, Noam shares his knowledge on reprogramming the immune system for better diagnosis and treatment. He shares his amazing team and how they make patient’s lives easier and meaningful. Tune in to learn more about immunotherapies!Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/